Dr. Martens (LON:DOCS) Trading Down 12.6% – Should You Sell?

Dr. Martens plc (LON:DOCS) shares dropped 12.6% on Tuesday . The stock traded as low as GBX 65 and last traded at GBX 66.10. Approximately 4,806,140 shares were traded during trading, an increase of 166% from the average daily volume of 1,808,856 shares. The stock had previously closed at GBX 75.65.

Dr. Martens News Summary

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Berenberg reaffirmed a “buy” rating on DOCS, which supports a constructive view from at least one broker and can provide a floor for sentiment. Berenberg Buy Reaffirmed Broker Notes on LSE
• Neutral Sentiment: Trading showed elevated volume vs. average, suggesting the move is driven by active repositioning rather than thin liquidity; keep an eye on follow-through volume and whether buy-side interest re-emerges. (Background: DOCS has a relatively high P/E and leverage that can amplify sentiment-driven moves.)
• Negative Sentiment: Management now expects flat revenue for fiscal 2026 as it scales back discounting — this signals weaker top‑line growth than investors may have hoped, even if margin benefits from fewer discounts are possible; the guidance is the primary driver of the negative market reaction. Dr Martens projects flat 2026 revenue

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DOCS. Berenberg Bank reaffirmed a “buy” rating on shares of Dr. Martens in a research report on Tuesday. Peel Hunt reaffirmed a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of GBX 6,000.

Dr. Martens Trading Down 11.6%

The firm has a fifty day moving average price of GBX 76.53 and a 200-day moving average price of GBX 83.47. The company has a market capitalization of £646.63 million, a P/E ratio of 39.35, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13.

Dr. Martens (LON:DOCS) last posted its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, equities research analysts anticipate that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Robert Hanson bought 96,000 shares of the company’s stock in a transaction on Friday, December 5th. The shares were purchased at an average cost of GBX 79 per share, for a total transaction of £75,840. Insiders have bought 97,130 shares of company stock valued at $7,673,816 in the last 90 days. 2.79% of the stock is owned by insiders.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.